Latest news with #DYN
Business Insider
12-07-2025
- Business
- Business Insider
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a 'notable lengthening' of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
18-06-2025
- Business
- Yahoo
Dyne at ‘attractive entry point' following pullback, says Chardan
Chardan notes Dyne Therapeutics (DYN) announced updates for its DYNE-101 program for myotonic dystrophy type 1, which included an update on regulatory alignment with the FDA regarding an accelerated approval pathway and updated data, out to 12-months, for the 6.8 mg/kg dose from the ACHIEVE trial. An accelerated approval pathway for DYNE-101 targeting DM1 requires the company to revise the protocol for the registrational expansion cohort of the ACHIEVE trial, switching to video hand opening time as the primary endpoint, notes the analyst, who believes that the confirmation by the FDA of an accelerated approval pathway 'more than offsets' what could be a six month delay from prior estimates of a BLA submission. The firm, which maintains its Buy rating and 12-month price target of $50 on Dyne shares, argues that with the stock having declined 41% year-to-date at yesterday's close that the current stock price 'represents an attractive entry point.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DYN: Disclaimer & DisclosureReport an Issue Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly Dyne Therapeutics: Strategic Shift to vHOT and FDA Support Bolster Buy Rating Dyne Therapeutics pivot on primary endpoint will 'raise questions,' says Stifel Dyne Therapeutics sinks 20% after changing study endpoint Dyne Therapeutics Granted Breakthrough Therapy Designation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the live webcast and replay, please visit About Dyne Therapeutics Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit and follow us on X, LinkedIn and Facebook. Contacts:InvestorsMia Tobiasir@ 781-317-0353 MediaStacy Nartkersnartker@ 781-317-1938
Business Insider
11-06-2025
- Business
- Business Insider
Dyne Therapeutics assumed with an Outperform at Raymond James
Raymond James analyst Martin Auster assumed coverage of Dyne Therapeutics (DYN) with an Outperform rating and $37 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS – probability of success – lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the stock, the firm notes that while it is trading at an enterprise value below $1B, Dyne's increasingly clinically-validated FORCE platform offers a compelling long-term risk-reward with proof of concept established on two assets in valuable, high unmet need markets, Raymond James added. Confident Investing Starts Here:
Yahoo
12-03-2025
- Business
- Yahoo
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12.03. Warning! GuruFocus has detected 3 Warning Signs with DYN. Using its TfR1-targeted delivery system, Dyne focuses in creating therapies for neuromuscular disorders. Key clinical initiatives of the business include its myotonic dystrophy type 1 therapy, now in Phase I/II studies, and its Duchenne muscular dystrophy treatment, which might be commercialized by 2026. The FDA's ruling on Dyne's DM1 therapy is a main determinant of her market course. The date of clearance might affect its capacity to access the market in relation to Avidity, a rival company in the field. Analysts advise Dyne may set itself apart by providing a therapy with advantages for central nervous systems. With a current ratio of 15.6 and a market capitalization of $1.37 billion, the firm shows good liquidity. With a beta of 1.11, it has only little connection with the larger market. Some analysts see a possible buying chance in the stock as it has down 51.19% year to date. Important forthcoming events include possibly accelerated approval applications for DYNE-251 and DYNE-101 in 2026. Early January 2025 will also include results from the DM1 Phase 1/2 ACHIEVE study, which will offer information on functional outcomes and splicing repair. Investor mood is still divided; substantial upward potential depends on clinical benchmarks and regulatory clearance routes. Although concerns still relate to regulatory choices and competitive market positioning, analysts stress the company's strong liquidity and pipeline developments. This article first appeared on GuruFocus. Sign in to access your portfolio
